IVIG for Small Fiber Neuropathy: Who Benefits and What to Expect

Intravenous immunoglobulin (IVIG) is a treatment derived from pooled human plasma that modulates the immune system. It has been used for decades in autoimmune neurological conditions including Guillain-Barré syndrome, CIDP, and myasthenia gravis. In recent years, evidence has accumulated supporting its use in autoimmune small fiber neuropathy (SFN), particularly in patients with documented autoantibodies or a clear autoimmune etiology.

The Autoimmune Basis of SFN

A significant proportion of SFN cases — particularly those with non-length-dependent patterns or associated dysautonomia — have an autoimmune basis. Identified autoantibodies include:

• Anti-CASPR2: Associated with peripheral nerve hyperexcitability, autonomic dysfunction, and SFN
• Anti-FGFR3: Associated with ataxic neuropathy and SFN
• Anti-TS-HDS: Strongly associated with painful SFN with autonomic features
• Anti-beta-adrenergic and anti-muscarinic: Associated with autonomic SFN and POTS

In patients with these autoantibodies, the immune system is attacking the small nerve fibers, and immunotherapy (including IVIG) may halt or reverse this damage.

Evidence for IVIG in SFN

The Oaklander study (2017): A randomized controlled trial of IVIG versus placebo in 60 SFN patients found significant improvement in pain, quality of life, and IENFD (nerve fiber density) in the IVIG group at 6 months. Patients with autoantibodies showed greater benefit.

Observational studies: Multiple case series have reported improvement in pain, autonomic symptoms, and IENFD following IVIG in SFN patients with autoimmune features. Improvement in IENFD — actual regrowth of nerve fibers — is particularly significant as it demonstrates disease modification rather than just symptom management.

Long COVID SFN: A 2023 German case series reported significant improvement in Long COVID patients with SFN and POTS following IVIG, with normalization of IENFD in some patients after 6 months of treatment.

Who Is Most Likely to Benefit

IVIG is most likely to benefit SFN patients who have:

1. Documented autoantibodies (anti-CASPR2, anti-FGFR3, anti-TS-HDS, or autonomic receptor antibodies)
2. Associated autoimmune conditions (Sjogren's, lupus, celiac disease)
3. Non-length-dependent SFN pattern (suggesting immune-mediated rather than metabolic cause)
4. Rapidly progressive symptoms (suggesting active immune attack)
5. Significant autonomic involvement (POTS, gastroparesis, anhidrosis)

Patients with length-dependent SFN from metabolic causes (diabetes, B12 deficiency) are less likely to benefit from IVIG.

What to Expect

Dosing: The standard IVIG dose for SFN is 1–2 g/kg over 2–5 days, repeated every 4–8 weeks. Some patients receive maintenance doses every 6–8 weeks after an initial loading course.

Response timeline: Improvement in pain and autonomic symptoms may occur within days to weeks of the first infusion. Improvement in IENFD (nerve fiber regrowth) takes longer — typically 3–6 months of regular treatment.

Side effects: Common side effects include headache (often severe, from aseptic meningitis), fatigue, flu-like symptoms, and infusion reactions. Premedication with acetaminophen, diphenhydramine, and hydration reduces these. Rare but serious risks include thrombosis, hemolysis, and renal failure.

Insurance coverage: IVIG is expensive ($10,000–$30,000 per infusion course) and insurance coverage for SFN is variable. Documentation of autoantibodies, failed conservative treatments, and functional impairment strengthens coverage requests. Some patients access IVIG through clinical trials.

Subcutaneous Immunoglobulin (SCIG)

For patients who respond to IVIG but find infusion center visits burdensome, subcutaneous immunoglobulin (SCIG) — self-administered weekly at home — is an alternative. SCIG provides more stable immunoglobulin levels with fewer side effects than monthly IVIG infusions and is increasingly used for maintenance therapy.

ChatDys resources: Track your neuropathic pain and autonomic symptoms before and after IVIG in the Health Tracker. Upload your autoantibody results to Biomarkers. If you have Long COVID SFN, review our Long COVID treatment trials article for information on the evidence base.